» Articles » PMID: 32025852

Cytokine Pre-activation of Cryopreserved Xenogeneic-free Human Mesenchymal Stromal Cells Enhances Resolution and Repair Following Ventilator-induced Lung Injury Potentially Via a KGF-dependent Mechanism

Overview
Specialty Critical Care
Date 2020 Feb 7
PMID 32025852
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Human mesenchymal stem/stromal cells (hMSCs) represent a promising therapeutic strategy for ventilator-induced lung injury (VILI) and acute respiratory distress syndrome. Translational challenges include restoring hMSC efficacy following cryopreservation, developing effective xenogeneic-free (XF) hMSCs and establishing true therapeutic potential at a clinically relevant time point of administration. We wished to determine whether cytokine pre-activation of cryopreserved, bone marrow-derived XF-hMSCs would enhance their capacity to facilitate injury resolution following VILI and elucidate mechanisms of action.

Methods: Initially, in vitro studies examined the potential for the secretome from cytokine pre-activated XF-hMSCs to attenuate pulmonary epithelial injury induced by cyclic mechanical stretch. Later, anaesthetised rats underwent VILI and, 6 h following injury, were randomized to receive 1 × 10 XF-hMSC/kg that were (i) naive fresh, (ii) naive cryopreserved, (iii) cytokine pre-activated fresh or (iv) cytokine pre-activated cryopreserved, while control animals received (v) vehicle. The extent of injury resolution was measured at 24 h after injury. Finally, the role of keratinocyte growth factor (KGF) in mediating the effect of pre-activated XF-hMSCs was determined in a pulmonary epithelial wound repair model.

Results: Pre-activation enhanced the capacity of the XF-hMSC secretome to decrease stretch-induced pulmonary epithelial inflammation and injury. Both pre-activated fresh and cryopreserved XF-hMSCs enhanced resolution of injury following VILI, restoring oxygenation, improving lung compliance, reducing lung leak and improving resolution of lung structural injury. Finally, the secretome of pre-activated XF-hMSCs enhanced epithelial wound repair, in part via a KGF-dependent mechanism.

Conclusions: Cytokine pre-activation enhanced the capacity of cryopreserved, XF-hMSCs to promote injury resolution following VILI, potentially via a KGF-dependent mechanism.

Citing Articles

Manipulated mesenchymal stem cell therapy in the treatment of Parkinson's disease.

Ekrani S, Mahmoudi M, Haghmorad D, Kheder R, Hatami A, Esmaeili S Stem Cell Res Ther. 2024; 15(1):476.

PMID: 39696636 PMC: 11657756. DOI: 10.1186/s13287-024-04073-9.


Advances of mesenchymal stem cells and their derived extracellular vesicles as a promising therapy for acute respiratory distress syndrome: from bench to clinic.

Zhuang X, Jiang Y, Yang X, Fu L, Luo L, Dong Z Front Immunol. 2023; 14:1244930.

PMID: 37711624 PMC: 10497773. DOI: 10.3389/fimmu.2023.1244930.


Boosting therapeutic efficacy of mesenchymal stem cells in pulmonary fibrosis: The role of genetic modification and preconditioning strategies.

Mehrabani M, Mohammadyar S, Rajizadeh M, Bejeshk M, Ahmadi B, Nematollahi M Iran J Basic Med Sci. 2023; 26(9):1001-1015.

PMID: 37605719 PMC: 10440137. DOI: 10.22038/IJBMS.2023.69023.15049.


Differential Effects of Cytokine Versus Hypoxic Preconditioning of Human Mesenchymal Stromal Cells in Pulmonary Sepsis Induced by Antimicrobial-Resistant .

Byrnes D, Masterson C, Brady J, Alagesan S, Gonzalez H, McCarthy S Pharmaceuticals (Basel). 2023; 16(2).

PMID: 37259300 PMC: 9961251. DOI: 10.3390/ph16020149.


Functional enhancement strategies to potentiate the therapeutic properties of mesenchymal stromal cells for respiratory diseases.

Lopes-Pacheco M, Rocco P Front Pharmacol. 2023; 14:1067422.

PMID: 37007034 PMC: 10062457. DOI: 10.3389/fphar.2023.1067422.


References
1.
McAuley D, Curley G, Hamid U, Laffey J, Abbott J, McKenna D . Clinical grade allogeneic human mesenchymal stem cells restore alveolar fluid clearance in human lungs rejected for transplantation. Am J Physiol Lung Cell Mol Physiol. 2014; 306(9):L809-15. PMC: 4010648. DOI: 10.1152/ajplung.00358.2013. View

2.
Curley G, Hayes M, Ansari B, Shaw G, Ryan A, Barry F . Mesenchymal stem cells enhance recovery and repair following ventilator-induced lung injury in the rat. Thorax. 2011; 67(6):496-501. DOI: 10.1136/thoraxjnl-2011-201059. View

3.
Ionescu L, Byrne R, van Haaften T, Vadivel A, Alphonse R, Rey-Parra G . Stem cell conditioned medium improves acute lung injury in mice: in vivo evidence for stem cell paracrine action. Am J Physiol Lung Cell Mol Physiol. 2012; 303(11):L967-77. PMC: 3532523. DOI: 10.1152/ajplung.00144.2011. View

4.
Mackensen A, Drager R, Schlesier M, Mertelsmann R, Lindemann A . Presence of IgE antibodies to bovine serum albumin in a patient developing anaphylaxis after vaccination with human peptide-pulsed dendritic cells. Cancer Immunol Immunother. 2000; 49(3):152-6. PMC: 11036962. DOI: 10.1007/s002620050614. View

5.
Monsel A, Zhu Y, Gennai S, Hao Q, Hu S, Rouby J . Therapeutic Effects of Human Mesenchymal Stem Cell-derived Microvesicles in Severe Pneumonia in Mice. Am J Respir Crit Care Med. 2015; 192(3):324-36. PMC: 4584251. DOI: 10.1164/rccm.201410-1765OC. View